Amicus Therapeutics, Inc. (FOLD)
$11.025
Rating:
Recommendation:
Buy
| Symbol | FOLD |
|---|---|
| Price | $11.025 |
| Beta | 0.865 |
| Volume Avg. | 2.44M |
| Market Cap | 3.233B |
| Shares () | - |
| 52 Week Range | 9.7-14.1 |
| 1y Target Est | - |
| DCF Unlevered | FOLD DCF -> | |
|---|---|---|
| DCF Levered | FOLD LDCF -> | |
| ROE | -147.61% | Strong Sell |
| ROA | -22.72% | Sell |
| Operating Margin | - | |
| Debt / Equity | 340.96% | Strong Buy |
| P/E | -18.69 | Strong Sell |
| P/B | 24.47 | Strong Buy |
Latest FOLD news
About
Download (Excel)Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.